Clinical lipid management of patients with mild-to-moderate hypertriglyceridemia

References

• Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch.Intern.Med. 169, 572–578 (2009).
   Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G etal. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 115, 450–458 (2007).
   Google Scholar
• Miller M, Stone NJ, Ballantyne C etal.; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123, 2292–2333 (2011).
   Google Scholar
• Kuklina EV, Keenan NL, Callaghan WM, Hong Y. Risk of cardiovascular mortality in relation to optimal low-density lipoprotein cholesterol combined with hypertriglyceridemia: is there a difference by gender? Ann.Epidemiol. 21, 807–814 (2011).
   Google Scholar
• Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best available evidence. J.Clin.Lipidol. doi:10.1016/j.jacl.2012.04.003 (2012) (Epub ahead of print).
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN etal. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
   Google Scholar
• Davidson MH, Maki KC, Pearson TA etal. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations. Am.J.Cardiol. 96, 556–563 (2005).
   Google Scholar
• Boekholdt SM, Arsenault BJ, Mora S etal. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307, 1302–1309 (2012).
   Google Scholar
• Maki KC. Fibrates for treatment of the metabolic syndrome. Curr.Atheroscler.Rep. 6, 45–51 (2004).
   Google Scholar
• Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription w-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoproteinassociated phospholipase A2 mass in men and women with mixed dyslipidemia. J.Clin. Lipidol. 5, 483–492 (2011).
   Google Scholar
• Ginsberg HN, Brown WV. Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler.Thromb.Vasc. Biol. 31, 471–473 (2011).
   Google Scholar
• Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E. Effects of prescription w-3 acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin.Proc. 85, 122–128 (2010).
   Google Scholar
• Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am.J.Clin.Nutr. 65(Suppl. 5), S1645–S1654 (1997).
   Google Scholar
• Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R; TRIMS investigators. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin.Cardiol. 29, 268–273 (2006).
   Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ etal. AMR101 lowers triglycerides, atherogenic lipoprotein, phospholipase A2, and highsensitivity C-reactive protein levels in patients with high triglycerides and on background statin therapy (the ANCHOR study). Circulation 124, Abstract 15071 (2011).
   Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels [from the multi-center, placebocontrolled, randomized, double-blind, 12-week study with open-label extension (MARINE) trial]. Am.J.Cardiol. 108, 682–690 (2011).
   Google Scholar
• Boden WE, Probstfield JL, Anderson T etal.; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N.Engl.J.Med. 365, 2255–2267 (2011).
   Google Scholar
• Eleftheriadou I, Grigoropoulou P, Katsilambros N, Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr.DiabetesRev. 4, 340–356 (2008).
   Google Scholar
• Davidson MH, Robinson JG. Lipid-lowering effects of statins: a comparative review. Expert OpinPharmacother. 7, 1701–1714 (2006).
   Google Scholar
• Maki KC, Dicklin MR, Lawless A, Reeves MS. w-3 fatty acids for the treatment of elevated triglycerides. Clin.Lipidol. 4, 425–437 (2009).
   Google Scholar
• Saito Y, Yokoyama M, Origasa H etal;JELIS investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS). Atherosclerosis 200, 135–140 (2008).
   Google Scholar
• Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J.Am. Coll.Cardiol. 55, 1283–1299 (2010).
   Google Scholar